Oppenheimer Keeps Summit Therapeutics (SMMT) at 'Outperform' Amid New DMD Deal (SRPT)

Summit Therapeutics (SMMT) PT Raised to $30 at Needham & Company Amid Sarepta Deal

October 4, 2016 1:38 PM EDT

Needham & Company analyst Chad Messer reiterated a Buy rating and raised his price target on Summit Therapeutics plc (NASDAQ: SMMT) to $30.00 (from $22.00) after the company licensed out European rights to Phase II candidate ezutromid to Sarepta.

Messer commented, "We believe this deal... More

Baird Remains Positive on Sarepta (SRPT) Amid New DMD Deal; Affirms at 'Outperform'

October 4, 2016 9:13 AM EDT

Baird affirms Sarepta Therapeutics (Nasdaq: SRPT) at Outperform with a price target of $102 following a new licensing agreement with Summit Therapeutics (Nasdaq: SMMT).

Analyst Brian Skorney noted that there was no change to the firm's outlook on Sarepta... More

Sarepta (SRPT) Deal with Summit Removes a Competitive Threat and Increases its Takeover Attractiveness - RBC

October 4, 2016 9:01 AM EDT

RBC Capital analyst Simos Simeonidis said he likes Sarepta Therapeutic (NASDAQ: SRPT) EU/LatAm partnership with Summit (NASDAQ: SMMT), as it removes a potential competitive threat with just $40M for access to competitor's drugs. He also said it makes the Sarepta more attractive as a takeover.

"Buying into this early-stage potential... More

Summit Therapeutics (SMMT) Surges 80% on Sarepta (SRPT) Deal

October 4, 2016 8:56 AM EDT

Summit Therapeutics (NASDAQ: SMMT) is trading up 80% in pre-open trade after the company entered an exclusive... More

Deal Positive for Sarepta (SRPT), Summit (SMMT) and DMD Community - Oppenheimer

October 4, 2016 8:44 AM EDT

Oppenheimer analyst Michelle Gilson reiterated an Outperform rating and $76 price target on Sarepta Therapeutic (NASDAQ: SRPT) after the company Sarepta and Summit (NASDAQ: SMMT) announced a licensing and collaboration agreement for EU rights to Summit's utrophin modulation programs... More

Threat of 'hard Brexit' pulls down Wall Street

October 4, 2016 7:44 AM EDT

By Noel Randewich

(Reuters) - U.S. stocks dropped on Tuesday as investors fretted about Britain's exit from the European Union and the prospect of a Federal Reserve interest rate hike in coming months.

It was the second straight session of losses on Wall Street, where investors were already on edge due to the uncertainty of a tight race ahead of the Nov. 8 presidential election.

Sterling slid to its lowest in more than three decades after British Prime Minister Theresa May said the country's divorce from the EU will not be "plain sailing" and... More

Summit Therapeutics (SMMT) will resume trading at 7:30am ET

October 4, 2016 7:08 AM EDT

Summit Therapeutics (NASDAQ: SMMT) will resume trading at 7:30am EDT.

... More